[go: up one dir, main page]

ES2397889A1 - PÉPTIDOS MODULADORES DE PGC-1Alfa. - Google Patents

PÉPTIDOS MODULADORES DE PGC-1Alfa. Download PDF

Info

Publication number
ES2397889A1
ES2397889A1 ES201130439A ES201130439A ES2397889A1 ES 2397889 A1 ES2397889 A1 ES 2397889A1 ES 201130439 A ES201130439 A ES 201130439A ES 201130439 A ES201130439 A ES 201130439A ES 2397889 A1 ES2397889 A1 ES 2397889A1
Authority
ES
Spain
Prior art keywords
pgc
1alpha
modulating peptides
peptides
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201130439A
Other languages
English (en)
Other versions
ES2397889B1 (es
Inventor
José María GARCÍA ANTÓN
Juan Cebrián Puche
Antonio Vicente Ferrer Montiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipotec SA
Original Assignee
Lipotec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201130439A priority Critical patent/ES2397889B1/es
Application filed by Lipotec SA filed Critical Lipotec SA
Priority to US14/006,981 priority patent/US9266921B2/en
Priority to ES12710106.1T priority patent/ES2600852T3/es
Priority to PCT/EP2012/055259 priority patent/WO2012130775A1/en
Priority to AU2012234370A priority patent/AU2012234370B2/en
Priority to BR112013020002-2A priority patent/BR112013020002B1/pt
Priority to JP2014500420A priority patent/JP6431367B2/ja
Priority to CN201280005815.8A priority patent/CN103379911B/zh
Priority to EP12710106.1A priority patent/EP2651428B1/en
Priority to KR1020137027976A priority patent/KR101988676B1/ko
Publication of ES2397889A1 publication Critical patent/ES2397889A1/es
Application granted granted Critical
Publication of ES2397889B1 publication Critical patent/ES2397889B1/es
Priority to JP2018132988A priority patent/JP2018193381A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/742—Coffea, e.g. coffee
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Birds (AREA)

Abstract

Péptidos de fórmula general (I):#****IMAGEN****#sus estereoisómeros, mezclas de los mismos y/o sus sales cosmética o farmacéuticamente aceptables, un procedimiento de preparación, composiciones cosméticas o farmacéuticas que los contienen y su uso para el tratamiento y/o cuidado de condiciones, desórdenes y/o enfermedades que mejoran o son prevenidos por la modulación de PGC-1{al}.
ES201130439A 2011-03-25 2011-03-25 PÉPTIDOS MODULADORES DE PGC-1Alfa. Expired - Fee Related ES2397889B1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES201130439A ES2397889B1 (es) 2011-03-25 2011-03-25 PÉPTIDOS MODULADORES DE PGC-1Alfa.
EP12710106.1A EP2651428B1 (en) 2011-03-25 2012-03-23 Pgc-1alpha-modulating peptides
PCT/EP2012/055259 WO2012130775A1 (en) 2011-03-25 2012-03-23 Pgc-1alpha-modulating peptides
AU2012234370A AU2012234370B2 (en) 2011-03-25 2012-03-23 PGC-1alpha-modulating peptides
BR112013020002-2A BR112013020002B1 (pt) 2011-03-25 2012-03-23 Peptídeo de fórmula geral r1-wn-xm-aa1-aa2-aa3-aa4-aa5-aa6-yp-zq-r2, seus estereoisômeros, misturas dos mesmos e/ou seus sais aceitáveis de modo cosmético ou farmacêutico e composição cosmética ou farmacêutica
JP2014500420A JP6431367B2 (ja) 2011-03-25 2012-03-23 ＰＧＣ−１αを調節するペプチド
US14/006,981 US9266921B2 (en) 2011-03-25 2012-03-23 PGC-1α-modulating peptides
ES12710106.1T ES2600852T3 (es) 2011-03-25 2012-03-23 Péptidos moduladores de PGC-1ALFA
KR1020137027976A KR101988676B1 (ko) 2011-03-25 2012-03-23 Pgc-1알파 조절 펩티드
CN201280005815.8A CN103379911B (zh) 2011-03-25 2012-03-23 PGC-1α调节肽
JP2018132988A JP2018193381A (ja) 2011-03-25 2018-07-13 ＰＧＣ−１αを調節するペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201130439A ES2397889B1 (es) 2011-03-25 2011-03-25 PÉPTIDOS MODULADORES DE PGC-1Alfa.

Publications (2)

Publication Number Publication Date
ES2397889A1 true ES2397889A1 (es) 2013-03-12
ES2397889B1 ES2397889B1 (es) 2014-02-07

Family

ID=46929508

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201130439A Expired - Fee Related ES2397889B1 (es) 2011-03-25 2011-03-25 PÉPTIDOS MODULADORES DE PGC-1Alfa.
ES12710106.1T Active ES2600852T3 (es) 2011-03-25 2012-03-23 Péptidos moduladores de PGC-1ALFA

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12710106.1T Active ES2600852T3 (es) 2011-03-25 2012-03-23 Péptidos moduladores de PGC-1ALFA

Country Status (9)

Country Link
US (1) US9266921B2 (es)
EP (1) EP2651428B1 (es)
JP (2) JP6431367B2 (es)
KR (1) KR101988676B1 (es)
CN (1) CN103379911B (es)
AU (1) AU2012234370B2 (es)
BR (1) BR112013020002B1 (es)
ES (2) ES2397889B1 (es)
WO (1) WO2012130775A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2976325B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of cyclic imide containing peptide products
WO2014147124A1 (en) 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
EP3247461B1 (en) * 2015-01-07 2020-11-25 Aboca S.p.A. Societa' Agricola Composition for lymph drainage
CN104622779A (zh) * 2015-01-08 2015-05-20 上海圣婕化妆品有限公司 一种多胜肽抗衰老修复面膜精华液及其制备方法
CN104523449A (zh) * 2015-01-08 2015-04-22 上海圣婕化妆品有限公司 一种抗衰老多胜肽复合物及其应用
WO2017136600A1 (en) 2016-02-04 2017-08-10 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
US10493020B2 (en) 2016-04-14 2019-12-03 The Procter & Gamble Company Method of improving the appearance of periorbital dyschromia
CN106943589B (zh) * 2017-05-19 2020-07-10 天津医科大学总医院 PGC-1α在制备治疗血管性痴呆药物中的用途
CN111182914A (zh) 2017-08-03 2020-05-19 阿拉斯廷护肤公司 用于改善皮肤松弛和身体轮廓的组合物和方法
CN107325157B (zh) * 2017-08-07 2020-06-26 温州千瑞生物科技有限公司 调节皮脂分泌的肽以及包含其的化妆品
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
JP2022509359A (ja) 2018-10-26 2022-01-20 ガラニン、アイバン 生体内での最適な真皮白色脂肪組織形成を促進するための局所組成物および方法
TR201901740A2 (tr) * 2019-02-05 2019-03-21 Dr Seyda Atabay Saglik Ve Kozmetik Ueruenleri A S Gözalti morluklarinin tedavi̇si̇ i̇çi̇n jel bazli formülasyon
CN109750012B (zh) * 2019-03-27 2021-10-15 云南师范大学 一种脂肪酶突变体及其应用
CN115209887A (zh) * 2019-12-30 2022-10-18 罗丹菲尔茨有限责任公司 Ppar激动剂复合物及其使用方法
CN112043627B (zh) * 2020-09-04 2023-02-03 高颜苑科技(深圳)有限责任公司 一种毛发生长的氨基酸溶液组合物及其制备方法
JP2024508747A (ja) * 2021-02-17 2024-02-28 アラスティン・スキンケア・インコーポレイテッド 脱毛症に関する組成物及び方法
CN115670965B (zh) * 2021-05-17 2024-04-19 杭州朝与暮品牌管理有限公司 一种有效抑制IL-8、TNF-α和IL-6的皮肤抗炎组合物
JP2024543222A (ja) 2021-12-03 2024-11-19 フンダチオ ホスピタル ウニベルシタリ ヴァルデブロン‐インスティテュート デ レセルカ 脂肪分解ペプチド
CN113980097B (zh) * 2021-12-29 2022-03-29 浙江湃肽生物有限公司南京分公司 棕榈酰三肽-5的纯化方法
CN117462440B (zh) * 2023-12-26 2024-09-13 杭州湃肽生化科技有限公司 功能性环肽及其制备方法及应用
CN119978067B (zh) * 2025-03-10 2025-08-15 山东美之健医药科技有限公司 一种保护肝脏、改善胃肠的洋蓟抗氧化肽及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032215A1 (en) * 1998-12-01 2000-06-08 Dana-Farber Cancer Institute PGC-1, A NOVEL BROWN FAT PPARη COACTIVATOR

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348943A (en) 1985-02-08 1994-09-20 Procyte Corporation Cosmetic and skin treatment compositions
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US20030044475A1 (en) 2000-03-24 2003-03-06 Van De Wiel Andriaan Emanuel Hendricus Anna Maria Cosmetic use of hop and ornithine
AU2002215956A1 (en) * 2000-10-17 2002-04-29 Bayer Aktiengesellschaft Regulation of human pgc-1-like protein
EP1331934B1 (de) 2000-11-09 2006-03-29 Phenion GmbH & Co KG Ppar-alpha,beta-aktivatoren zur behandlung von alopecia areata und vitiligo
GB2369572A (en) 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
EP1234572B1 (de) 2001-02-26 2013-10-30 Mibelle AG Cosmetics Isoflavon-Aglykone enhaltende Hautbehandlungsmittel
WO2002087576A1 (en) 2001-04-30 2002-11-07 Arachnova Therapeutics Ltd. The treatment of scarring and related conditions using ppar-gamma activators
EP1513558A4 (en) 2002-02-13 2005-11-23 Dana Farber Cancer Inst Inc METHOD AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION WITH PGC-1a
US8513407B2 (en) 2002-06-18 2013-08-20 Glycores 2000 S.R.L. Process for the preparation of N-acyl-(epi)K5-amine-O-sulfate-derivatives and products thus obtained
FR2874379B1 (fr) 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
US7947652B2 (en) 2004-09-03 2011-05-24 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating PGC-1α to treat huntington's disease
US7618662B2 (en) 2004-12-22 2009-11-17 Avon Products, Inc Use of natural plant extracts in cosmetic compositions
US7410658B2 (en) 2004-12-22 2008-08-12 Avon Products, Inc. Use of Alisma orientale in cosmetics and compositions thereof
BRPI0500959A (pt) 2005-03-23 2006-11-21 Unicamp uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos
CN100368562C (zh) * 2005-10-18 2008-02-13 卫生部北京医院 一种鉴定pgc-1基因启动子-1436位snp分子标记的引物、方法及试剂盒
JP2007217368A (ja) * 2006-02-17 2007-08-30 Japan Health Science Foundation ＰＧＣ−１α発現促進剤及びＰＧＣ−１α発現抑制剤、並びにそれらの使用方法
FR2904549B1 (fr) 2006-08-03 2012-12-14 Sederma Sa Composition comprenant de la sarsasapogenine
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
FR2941151B1 (fr) 2009-01-22 2012-05-11 Caster Extrait de lentinus pour son action sur la cellulite et les amas graisseux.
DE102009033740A1 (de) 2009-07-17 2011-02-03 Dr. Scheller Cosmetics Ag Kosmetische Zusammensetzung, insbesondere zur Anwendung bei Cellulite
WO2011025572A1 (en) * 2009-08-26 2011-03-03 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2010089421A2 (en) 2010-05-25 2010-08-12 Symrise Gmbh & Co. Kg Menthyl carbamate compounds as active anti-cellulite ingredients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032215A1 (en) * 1998-12-01 2000-06-08 Dana-Farber Cancer Institute PGC-1, A NOVEL BROWN FAT PPARη COACTIVATOR

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAGUCHI, H. et al. ¿Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2C¿, Wip1. BIOCHEMISTRY. 07.11.2006. Vol. 45, nº 44, páginas 13193-13202. Tabla 1, Figura 1B. *

Also Published As

Publication number Publication date
JP2014510091A (ja) 2014-04-24
EP2651428B1 (en) 2016-08-03
KR101988676B1 (ko) 2019-06-12
CN103379911B (zh) 2016-05-25
ES2397889B1 (es) 2014-02-07
US20140086981A1 (en) 2014-03-27
WO2012130775A1 (en) 2012-10-04
EP2651428A1 (en) 2013-10-23
BR112013020002A2 (pt) 2017-09-19
AU2012234370A1 (en) 2013-07-18
CN103379911A (zh) 2013-10-30
BR112013020002B1 (pt) 2022-10-04
JP2018193381A (ja) 2018-12-06
ES2600852T3 (es) 2017-02-13
JP6431367B2 (ja) 2018-11-28
US9266921B2 (en) 2016-02-23
KR20140041467A (ko) 2014-04-04
AU2012234370B2 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
AR086409A1 (es) Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
UY33483A (es) Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento.
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
ECSP14013215A (es) Compuestos novedosos
CU20170144A7 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2397889

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140207

NE2A Request for restoration [patent]

Effective date: 20160211

FD2A Announcement of lapse in spain

Effective date: 20220705